Development of innovative molecules for the treatment of central nervous system diseases

Development of innovative molecules for the treatment of central nervous system diseases
Neurolixis : innovation in biotechnology

Neurolixis : innovation in biotechnology
Neurolixis develops compounds in clinical phase and preclinical phase

Neurolixis develops compounds in clinical phase and preclinical phase

PROMISING PIPELINE

Neurolixis Inc. has in-licensed early-stage clinical assets (Phase 1 and Phase 2) for repurposing in indications with unmet needs in psychiatric and neurological disorders.

RESEARCH

Neurolixis has been awarded several research grants by private foundations, including Parkinson's UK, the Michael J. Fox Foundation for Parkinson's Research, the Rett Syndrome Research Trust and the International Rett Syndrome Foundation.

THERAPEUTIC FOCUS

Neurolixis is developing clinical phase drugs targeting dyskinesia in Parkinson's disease and breathing deficits in Rett syndrome, a devastating orphan disorder.

Neurolixis Innovation IN BiotechnologY

Neurolixis is an early-stage biopharmaceutical company focused on the discovery and development of novel drugs for the treatment of human central nervous system disorders including Parkinson's disease, Rett syndrome, depression and schizophrenia.

Neurolixis was founded by highly experienced pharmaceutical industry professionals, with a world-class track record of CNS drug discovery, drug development, clinical trials, and company management.

NLX-101 :  a treatment for Rett syndrome

NLX-101 (previously known as F15599) is a novel compound that activates serotonin 5-HT1A receptors [1] with exceptional selectivity, having over 1000-fold higher affinity for this target over other receptors. In addition, NLX-101 is a 'biased agonist' at 5-HT1A receptors, preferentially activating 5-HT1A receptors in those brain regions that control mood and cognition. In animal models, NLX-101 is very active in a rat test of antidepressant activity following a single administration, whereas currently used antidepressants require repeated administration to show activity. NLX-101 also robustly restores memory deficits. These pronounced antidepressant and cognitive enhancing properties are not seen with older 5-HT1A agonists.

NLX-112 : a treatment for Parkinson's disease

NLX-112 (also known as befiradol or F13640) is a novel compound that activates serotonin 5-HT1A receptors. NLX-112 has two main advantages over older compounds: 1. NLX-112 is extremely selective for the 5-HT1A receptor, with over 1000-fold selectivity compared to other types of receptor types, and 2. NLX-112 is a full agonist at 5-HT1A receptors, maximally activating the receptor.

Our team

Collaborations

News

Newsletter

Please enable the javascript to submit this form

Follow Neurolixis on: